DENVER, Jan. 4 /PRNewswire/ -- ARCA Discovery Inc., a privately held biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced Richard B. Brewer, President and Chief Executive Officer, will present at the 26th Annual JPMorgan Healthcare Conference on Tuesday, January 8 at 2:00 PM PT.
The JPMorgan Healthcare Conference will be held January 7-10, 2008 at the Westin St. Francis in San Francisco, California.
About ARCA Discovery, Inc.
ARCA Discovery, Inc. is a privately-held biopharmaceutical company based in Denver, Colorado developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company's first product is bucindolol, a next generation beta-blocker for chronic heart failure, which promises to be the first personalized, genetically-targeted cardiovascular therapy. ARCA plans to file for FDA approval of bucindolol in 2008, and to leverage its platform to develop other pharmacogenetic therapies for cardiovascular diseases. The Company recently closed a Series B round of $18 million, led by new investors Skyline Ventures and InterWest Partners. ARCA completed a $15 million Series A round in 2006 led by Atlas Venture and Boulder Ventures, which also participated in the Series B round.
ARCA has exclusive worldwide rights to bucindolol, a next generation
beta-blocker for chronic heart failure. ARCA's cardiovascular platform
combines expertise in cardiovascular pathophysiology, molecular genetics
and clinical development, in a unique approach that enables the efficient
identification of pharmacogenetic targets. Applying this approach to
bucindolol, ARCA has identified pathways affecting bucindolol response that
are modulated by common genetic variations. This discovery is supported by
substantial Phase 3 data, and will allow a physician to determine whether
bucindolol is the right therapy for a pati
|SOURCE ARCA Discovery Inc.|
Copyright©2008 PR Newswire.
All rights reserved